Review of NICE Technology Appraisal Guidance No.117; Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

Proposal to move guidance to the static list

The consideration of a review of TA117 was deferred in May 2010 until the results of the EVOLVE trial became available. 

The EVOLVE trial has now been published, and consequently the Institute has considered whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

The EVOLVE study did not show significant reductions in cardiovascular endpoints relative to placebo, which suggests that recommendation 1.1 does not require an update, and there is no new evidence that is likely to have a material effect on the recommendations 1.2 and 1.3. Consequently we propose that the original guidance become static.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted. 

April 2013